DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

Impact · against what's priced in

Acadia Pharmaceuticals receives a positive CHMP recommendation for DAYBU in the EU, significantly increasing the probability of European market entry for its Rett syndrome treatment. This provides a clear path to international revenue expansion beyond the US market.

ACAD+0.80

No priced-in read yet

In context

The CHMP's positive opinion for DAYBU in adults and children aged five and older creates a tangible path toward marketing authorization and new revenue streams in the European Union.

Read from the article alone

• biotech
• ACAD
• ema
• europe
• marketing authorization
• pharma
• rett syndrome

Search tags